The Schwank lab is part of the Institute of Pharmacology and Toxicology of the University Zurich. Our mission is to develop transformative technologies for the treatment genetic disorders. Much of our work involves the generation of novel genome editing technologies, and their application in animal models and human organoid models. Current research in our lab can be divided into two major areas:
1) The development of CRISPR-based genome editing approaches to correct monogenetic disorders of the liver and the brain.
2) The application of functional genomics approaches to develop targeted and personalized treatments for colorectal- and pancreatic cancer.